// App-Quantinova.ai

748P : Comparisons of outcomes of patients with advanced pancreatic cancer (APC) treated with FOLFIRINOX (FX) versus gemcitabine and nab-paclitaxel (GN): A population-based cohort study

Researchers

Presenter

  • N.Papneja

Principal Investigators

  • C.Olson

  • H.Chalchal

  • M.Moser

  • N.Iqbal

  • K.Haider

  • A.Zaidi

  • J.Shaw

  • B.Brunet

  • D-A.Dueck

  • T.Abbas

  • S.Ahmed

Medical Centers

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Pharmacy, Saskatchewan Cancer Agency, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, SK, Canada

  • Oncology, Saskatchewan Cancer Agency, Allan Blair Cancer Center, University of Saskatchewan, Regina, SK, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Pharmacy, Saskatchewan Cancer Agency, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, SK, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Adenomatous Polyposis Coli

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved